ID   GRK5_HUMAN              Reviewed;         590 AA.
AC   P34947; D3DRD0; Q5T059;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   12-OCT-2022, entry version 203.
DE   RecName: Full=G protein-coupled receptor kinase 5;
DE            EC=2.7.11.16;
DE   AltName: Full=G protein-coupled receptor kinase GRK5;
GN   Name=GRK5; Synonyms=GPRK5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=7685906; DOI=10.1073/pnas.90.12.5588;
RA   Kunapuli P., Benovic J.L.;
RT   "Cloning and expression of GRK5: a member of the G protein-coupled receptor
RT   kinase family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5588-5592(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INDUCTION.
RX   PubMed=8381058; DOI=10.1161/01.cir.87.2.454;
RA   Ungerer M., Bohm M., Elce J.S., Erdmann E., Lohse M.J.;
RT   "Altered expression of beta-adrenergic receptor kinase and beta 1-
RT   adrenergic receptors in the failing human heart.";
RL   Circulation 87:454-463(1993).
RN   [6]
RP   PHOSPHORYLATION AT SER-484 AND THR-485, AND MUTAGENESIS OF SER-484 AND
RP   THR-485.
RX   PubMed=8144599; DOI=10.1016/s0021-9258(17)34046-2;
RA   Kunapuli P., Gurevich V.V., Benovic J.L.;
RT   "Phospholipid-stimulated autophosphorylation activates the G protein-
RT   coupled receptor kinase GRK5.";
RL   J. Biol. Chem. 269:10209-10212(1994).
RN   [7]
RP   ACTIVITY REGULATION.
RX   PubMed=9218466; DOI=10.1074/jbc.272.29.18273;
RA   Pronin A.N., Satpaev D.K., Slepak V.Z., Benovic J.L.;
RT   "Regulation of G protein-coupled receptor kinases by calmodulin and
RT   localization of the calmodulin binding domain.";
RL   J. Biol. Chem. 272:18273-18280(1997).
RN   [8]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-550; LEU-551; LEU-554 AND
RP   PHE-555.
RX   PubMed=14976207; DOI=10.1074/jbc.m310738200;
RA   Thiyagarajan M.M., Stracquatanio R.P., Pronin A.N., Evanko D.S.,
RA   Benovic J.L., Wedegaertner P.B.;
RT   "A predicted amphipathic helix mediates plasma membrane localization of
RT   GRK5.";
RL   J. Biol. Chem. 279:17989-17995(2004).
RN   [9]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF
RP   ARG-388; LYS-389; LYS-391; LYS-393 AND ARG-394.
RX   PubMed=15542828; DOI=10.1128/mcb.24.23.10169-10179.2004;
RA   Johnson L.R., Scott M.G., Pitcher J.A.;
RT   "G protein-coupled receptor kinase 5 contains a DNA-binding nuclear
RT   localization sequence.";
RL   Mol. Cell. Biol. 24:10169-10179(2004).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-484 AND THR-485, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF ARRB1, AND INTERACTION WITH HTR4.
RX   PubMed=19661922; DOI=10.1038/emboj.2009.215;
RA   Barthet G., Carrat G., Cassier E., Barker B., Gaven F., Pillot M.,
RA   Framery B., Pellissier L.P., Augier J., Kang D.S., Claeysen S., Reiter E.,
RA   Baneres J.L., Benovic J.L., Marin P., Bockaert J., Dumuis A.;
RT   "Beta-arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-
RT   HT4 receptor signalling.";
RL   EMBO J. 28:2706-2718(2009).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF LRP6.
RX   PubMed=19801552; DOI=10.1074/jbc.m109.047456;
RA   Chen M., Philipp M., Wang J., Premont R.T., Garrison T.R., Caron M.G.,
RA   Lefkowitz R.J., Chen W.;
RT   "G Protein-coupled receptor kinases phosphorylate LRP6 in the Wnt
RT   pathway.";
RL   J. Biol. Chem. 284:35040-35048(2009).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF TP53, INTERACTION WITH TP53, AND MUTAGENESIS
RP   OF LYS-215.
RX   PubMed=20124405; DOI=10.1074/jbc.m109.094243;
RA   Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.;
RT   "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA
RT   damage-induced apoptosis.";
RL   J. Biol. Chem. 285:12823-12830(2010).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF ADRB2, AND AUTOPHOSPHORYLATION.
RX   PubMed=20038610; DOI=10.1124/mol.109.058115;
RA   Baameur F., Morgan D.H., Yao H., Tran T.M., Hammitt R.A., Sabui S.,
RA   McMurray J.S., Lichtarge O., Clark R.B.;
RT   "Role for the regulator of G-protein signaling homology domain of G
RT   protein-coupled receptor kinases 5 and 6 in beta 2-adrenergic receptor and
RT   rhodopsin phosphorylation.";
RL   Mol. Pharmacol. 77:405-415(2010).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF ST13, AND INTERACTION WITH ST13.
RX   PubMed=21728385; DOI=10.1021/bi2005202;
RA   Barker B.L., Benovic J.L.;
RT   "G protein-coupled receptor kinase 5 phosphorylation of Hip regulates
RT   internalization of the chemokine receptor CXCR4.";
RL   Biochemistry 50:6933-6941(2011).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-41; VAL-119; SER-122; MET-129; ILE-141;
RP   GLU-163 AND HIS-304.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [17]
RP   VARIANT LEU-41, CHARACTERIZATION OF VARIANT LEU-41, POLYMORPHISM, AND
RP   POSSIBLE PROTECTIVE ROLE IN THE PROGRESSION OF HEART FAILURE.
RX   PubMed=18425130; DOI=10.1038/nm1750;
RA   Liggett S.B., Cresci S., Kelly R.J., Syed F.M., Matkovich S.J., Hahn H.S.,
RA   Diwan A., Martini J.S., Sparks L., Parekh R.R., Spertus J.A., Koch W.J.,
RA   Kardia S.L., Dorn G.W. II;
RT   "A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is
RT   protective in heart failure.";
RL   Nat. Med. 14:510-517(2008).
CC   -!- FUNCTION: Serine/threonine kinase that phosphorylates preferentially
CC       the activated forms of a variety of G-protein-coupled receptors
CC       (GPCRs). Such receptor phosphorylation initiates beta-arrestin-mediated
CC       receptor desensitization, internalization, and signaling events leading
CC       to their down-regulation. Phosphorylates a variety of GPCRs, including
CC       adrenergic receptors, muscarinic acetylcholine receptors (more
CC       specifically Gi-coupled M2/M4 subtypes), dopamine receptors and opioid
CC       receptors. In addition to GPCRs, also phosphorylates various
CC       substrates: Hsc70-interacting protein/ST13, TP53/p53, HDAC5, and
CC       arrestin-1/ARRB1. Phosphorylation of ARRB1 by GRK5 inhibits G-protein
CC       independent MAPK1/MAPK3 signaling downstream of 5HT4-receptors.
CC       Phosphorylation of HDAC5, a repressor of myocyte enhancer factor 2
CC       (MEF2) leading to nuclear export of HDAC5 and allowing MEF2-mediated
CC       transcription. Phosphorylation of TP53/p53, a crucial tumor suppressor,
CC       inhibits TP53/p53-mediated apoptosis. Phosphorylation of ST13 regulates
CC       internalization of the chemokine receptor. Phosphorylates rhodopsin
CC       (RHO) (in vitro) and a non G-protein-coupled receptor, LRP6 during Wnt
CC       signaling (in vitro). {ECO:0000269|PubMed:19661922,
CC       ECO:0000269|PubMed:19801552, ECO:0000269|PubMed:20038610,
CC       ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:21728385}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[G-protein-coupled receptor] + ATP = [G-protein-coupled
CC         receptor]-phosphate + ADP + H(+); Xref=Rhea:RHEA:12008, Rhea:RHEA-
CC         COMP:11260, Rhea:RHEA-COMP:11261, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546,
CC         ChEBI:CHEBI:456216; EC=2.7.11.16;
CC   -!- ACTIVITY REGULATION: Inhibited by calmodulin with an IC(50) of 50 nM.
CC       Calmodulin inhibits GRK5 association with receptor and phospholipid.
CC       {ECO:0000269|PubMed:9218466}.
CC   -!- SUBUNIT: Interacts with ST13 (via the C-terminus 303-319 AA)
CC       (PubMed:21728385). Interacts with TP53/p53 (PubMed:20124405). Interacts
CC       with HTR4 (via C-terminus 330-346 AA); this interaction is promoted by
CC       5-HT (serotonin) (PubMed:19661922). Interacts with HDAC5 (By
CC       similarity). Interacts with GIT1 (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q62833, ECO:0000250|UniProtKB:Q8VEB1,
CC       ECO:0000269|PubMed:19661922, ECO:0000269|PubMed:20124405,
CC       ECO:0000269|PubMed:21728385}.
CC   -!- INTERACTION:
CC       P34947; P25963: NFKBIA; NbExp=2; IntAct=EBI-7149314, EBI-307386;
CC       P34947; P97288: Htr4; Xeno; NbExp=8; IntAct=EBI-7149314, EBI-7149283;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane; Peripheral
CC       membrane protein. Note=Predominantly localized at the plasma membrane;
CC       targeted to the cell surface through the interaction with
CC       phospholipids. Nucleus localization is regulated in a GPCR and
CC       Ca(2+)/calmodulin-dependent fashion.
CC   -!- TISSUE SPECIFICITY: Highest levels in heart, placenta, lung > skeletal
CC       muscle > brain, liver, pancreas > kidney. {ECO:0000269|PubMed:7685906}.
CC   -!- INDUCTION: Overexpressed during heart failure.
CC       {ECO:0000269|PubMed:8381058}.
CC   -!- PTM: Autophosphorylated. Autophosphorylation may play a critical role
CC       in the regulation of GRK5 kinase activity.
CC       {ECO:0000269|PubMed:8144599}.
CC   -!- POLYMORPHISM: Variant Leu-41 variant is rare in European-Americans
CC       individuals but common in African-Americans individuals (40% of the
CC       African-American individuals studied carry at least one allele).
CC       Variant leu-41 is associated with decreased mortality in African-
CC       Americans with heart failure or cardiac ischemia.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. GPRK subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L15388; AAA58620.1; -; mRNA.
DR   EMBL; AL355273; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355861; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL583824; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49394.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49395.1; -; Genomic_DNA.
DR   EMBL; BC064506; AAH64506.1; -; mRNA.
DR   CCDS; CCDS7612.1; -.
DR   PIR; A48277; A48277.
DR   PIR; B48682; B48682.
DR   RefSeq; NP_005299.1; NM_005308.2.
DR   PDB; 4TNB; X-ray; 2.11 A; A=1-590.
DR   PDB; 4TND; X-ray; 1.80 A; A=1-590.
DR   PDB; 6PJX; X-ray; 1.96 A; A=1-590.
DR   PDBsum; 4TNB; -.
DR   PDBsum; 4TND; -.
DR   PDBsum; 6PJX; -.
DR   AlphaFoldDB; P34947; -.
DR   SMR; P34947; -.
DR   BioGRID; 109127; 174.
DR   DIP; DIP-57457N; -.
DR   IntAct; P34947; 5.
DR   MINT; P34947; -.
DR   STRING; 9606.ENSP00000376609; -.
DR   BindingDB; P34947; -.
DR   ChEMBL; CHEMBL5678; -.
DR   GuidetoPHARMACOLOGY; 1469; -.
DR   iPTMnet; P34947; -.
DR   PhosphoSitePlus; P34947; -.
DR   BioMuta; GRK5; -.
DR   DMDM; 462203; -.
DR   jPOST; P34947; -.
DR   MassIVE; P34947; -.
DR   MaxQB; P34947; -.
DR   PaxDb; P34947; -.
DR   PeptideAtlas; P34947; -.
DR   PRIDE; P34947; -.
DR   ProteomicsDB; 54958; -.
DR   ABCD; P34947; 1 sequenced antibody.
DR   Antibodypedia; 18824; 535 antibodies from 38 providers.
DR   DNASU; 2869; -.
DR   Ensembl; ENST00000392870.3; ENSP00000376609.2; ENSG00000198873.12.
DR   GeneID; 2869; -.
DR   KEGG; hsa:2869; -.
DR   MANE-Select; ENST00000392870.3; ENSP00000376609.2; NM_005308.3; NP_005299.1.
DR   UCSC; uc001led.4; human.
DR   CTD; 2869; -.
DR   DisGeNET; 2869; -.
DR   GeneCards; GRK5; -.
DR   HGNC; HGNC:4544; GRK5.
DR   HPA; ENSG00000198873; Low tissue specificity.
DR   MIM; 600870; gene.
DR   neXtProt; NX_P34947; -.
DR   OpenTargets; ENSG00000198873; -.
DR   PharmGKB; PA180; -.
DR   VEuPathDB; HostDB:ENSG00000198873; -.
DR   eggNOG; KOG0986; Eukaryota.
DR   GeneTree; ENSGT00940000160702; -.
DR   HOGENOM; CLU_000288_63_41_1; -.
DR   InParanoid; P34947; -.
DR   OMA; YIVNRIF; -.
DR   OrthoDB; 1104340at2759; -.
DR   PhylomeDB; P34947; -.
DR   TreeFam; TF313940; -.
DR   BRENDA; 2.7.11.16; 2681.
DR   PathwayCommons; P34947; -.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   SignaLink; P34947; -.
DR   SIGNOR; P34947; -.
DR   BioGRID-ORCS; 2869; 14 hits in 1109 CRISPR screens.
DR   ChiTaRS; GRK5; human.
DR   GeneWiki; GRK5; -.
DR   GenomeRNAi; 2869; -.
DR   Pharos; P34947; Tchem.
DR   PRO; PR:P34947; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P34947; protein.
DR   Bgee; ENSG00000198873; Expressed in saphenous vein and 195 other tissues.
DR   Genevisible; P34947; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0047696; F:beta-adrenergic receptor kinase activity; IMP:CACAO.
DR   GO; GO:0004703; F:G protein-coupled receptor kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005543; F:phospholipid binding; TAS:ProtInc.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0005080; F:protein kinase C binding; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:CACAO.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:CACAO.
DR   GO; GO:0008277; P:regulation of G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0009966; P:regulation of signal transduction; IBA:GO_Central.
DR   GO; GO:0007217; P:tachykinin receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.167.10; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000239; GPCR_kinase.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016137; RGS.
DR   InterPro; IPR036305; RGS_sf.
DR   InterPro; IPR044926; RGS_subdomain_2.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00615; RGS; 1.
DR   PRINTS; PR00717; GPCRKINASE.
DR   SMART; SM00315; RGS; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48097; SSF48097; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS50132; RGS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Cell membrane; Cytoplasm; Kinase;
KW   Lipid-binding; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Wnt signaling pathway.
FT   CHAIN           1..590
FT                   /note="G protein-coupled receptor kinase 5"
FT                   /id="PRO_0000085971"
FT   DOMAIN          53..171
FT                   /note="RGS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00171"
FT   DOMAIN          186..448
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          449..514
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   REGION          1..185
FT                   /note="N-terminal"
FT   REGION          20..39
FT                   /note="Interaction with calmodulin"
FT   REGION          531..590
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          546..565
FT                   /note="Sufficient for membrane localization"
FT   MOTIF           388..395
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:15542828"
FT   COMPBIAS        555..590
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        311
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         192..200
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         215
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         484
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8144599,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         485
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8144599,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         579
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VEB1"
FT   VARIANT         41
FT                   /note="Q -> L (exerts a protective effect in heart failure
FT                   and ischemia; dbSNP:rs2230345)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:18425130"
FT                   /id="VAR_040517"
FT   VARIANT         119
FT                   /note="A -> V (in dbSNP:rs55980792)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040518"
FT   VARIANT         122
FT                   /note="G -> S (in dbSNP:rs55902633)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040519"
FT   VARIANT         129
FT                   /note="T -> M (in dbSNP:rs34679178)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040520"
FT   VARIANT         141
FT                   /note="L -> I (in dbSNP:rs56254855)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040521"
FT   VARIANT         163
FT                   /note="D -> E (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040522"
FT   VARIANT         304
FT                   /note="R -> H (in dbSNP:rs2230349)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040523"
FT   MUTAGEN         215
FT                   /note="K->R: Failed to phosphorylate p53/TP53."
FT                   /evidence="ECO:0000269|PubMed:20124405"
FT   MUTAGEN         388
FT                   /note="R->A: Nuclear exclusion; when associated with A-389;
FT                   A-391; A-393 and A-394."
FT                   /evidence="ECO:0000269|PubMed:15542828"
FT   MUTAGEN         389
FT                   /note="K->A: Nuclear exclusion; when associated with A-388;
FT                   A-391; A-393 and A-394."
FT                   /evidence="ECO:0000269|PubMed:15542828"
FT   MUTAGEN         391
FT                   /note="K->A: Nuclear exclusion; when associated with A-388;
FT                   A-389; A-393 and A-394."
FT                   /evidence="ECO:0000269|PubMed:15542828"
FT   MUTAGEN         393
FT                   /note="K->A: Nuclear exclusion; when associated with A-388;
FT                   A-389; A-391 and A-394."
FT                   /evidence="ECO:0000269|PubMed:15542828"
FT   MUTAGEN         394
FT                   /note="R->A: Nuclear exclusion; when associated with A-388;
FT                   A-389; A-391 and A-393."
FT                   /evidence="ECO:0000269|PubMed:15542828"
FT   MUTAGEN         484
FT                   /note="S->A: 15-20 fold defects in kinase activity; when
FT                   associated with A-485."
FT                   /evidence="ECO:0000269|PubMed:8144599"
FT   MUTAGEN         485
FT                   /note="T->A: 15-20 fold defects in kinase activity; when
FT                   associated with A-484."
FT                   /evidence="ECO:0000269|PubMed:8144599"
FT   MUTAGEN         550
FT                   /note="L->A: No detectable plasma membrane localization;
FT                   when associated with A-551; A-554; and A-555."
FT                   /evidence="ECO:0000269|PubMed:14976207"
FT   MUTAGEN         551
FT                   /note="L->A: No detectable plasma membrane localization;
FT                   when associated with A-550; A-554; and A-555."
FT                   /evidence="ECO:0000269|PubMed:14976207"
FT   MUTAGEN         554
FT                   /note="L->A: No detectable plasma membrane localization;
FT                   when associated with A-550; A-551; and A-555."
FT                   /evidence="ECO:0000269|PubMed:14976207"
FT   MUTAGEN         555
FT                   /note="F->A: No detectable plasma membrane localization;
FT                   when associated with A-550; A-551; and A-554."
FT                   /evidence="ECO:0000269|PubMed:14976207"
FT   HELIX           3..16
FT                   /evidence="ECO:0007829|PDB:6PJX"
FT   TURN            17..20
FT                   /evidence="ECO:0007829|PDB:6PJX"
FT   HELIX           22..25
FT                   /evidence="ECO:0007829|PDB:6PJX"
FT   HELIX           30..33
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           39..42
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           43..48
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           53..57
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           61..71
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           75..91
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           95..97
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           98..109
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           123..134
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   TURN            139..142
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           143..153
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           156..162
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           165..177
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          185..195
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          198..205
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   TURN            206..208
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          211..218
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           219..224
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           228..240
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          249..254
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          256..263
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          268..270
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           271..277
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          278..280
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           285..304
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           314..316
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          317..319
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          325..327
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           330..332
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           354..357
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          362..364
FT                   /evidence="ECO:0007829|PDB:6PJX"
FT   HELIX           366..380
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          384..386
FT                   /evidence="ECO:0007829|PDB:6PJX"
FT   HELIX           394..403
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           414..423
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           428..430
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   TURN            436..438
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           439..443
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           446..448
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           453..457
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           477..479
FT                   /evidence="ECO:0007829|PDB:6PJX"
FT   STRAND          489..491
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           494..502
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           508..517
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           520..524
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   STRAND          529..531
FT                   /evidence="ECO:0007829|PDB:4TND"
FT   HELIX           535..537
FT                   /evidence="ECO:0007829|PDB:4TND"
SQ   SEQUENCE   590 AA;  67787 MW;  D363567ECFF5CF21 CRC64;
     MELENIVANT VLLKAREGGG GKRKGKSKKW KEILKFPHIS QCEDLRRTID RDYCSLCDKQ
     PIGRLLFRQF CETRPGLECY IQFLDSVAEY EVTPDEKLGE KGKEIMTKYL TPKSPVFIAQ
     VGQDLVSQTE EKLLQKPCKE LFSACAQSVH EYLRGEPFHE YLDSMFFDRF LQWKWLERQP
     VTKNTFRQYR VLGKGGFGEV CACQVRATGK MYACKRLEKK RIKKRKGESM ALNEKQILEK
     VNSQFVVNLA YAYETKDALC LVLTIMNGGD LKFHIYNMGN PGFEEERALF YAAEILCGLE
     DLHRENTVYR DLKPENILLD DYGHIRISDL GLAVKIPEGD LIRGRVGTVG YMAPEVLNNQ
     RYGLSPDYWG LGCLIYEMIE GQSPFRGRKE KVKREEVDRR VLETEEVYSH KFSEEAKSIC
     KMLLTKDAKQ RLGCQEEGAA EVKRHPFFRN MNFKRLEAGM LDPPFVPDPR AVYCKDVLDI
     EQFSTVKGVN LDHTDDDFYS KFSTGSVSIP WQNEMIETEC FKELNVFGPN GTLPPDLNRN
     HPPEPPKKGL LQRLFKRQHQ NNSKSSPSSK TSFNHHINSN HVSSNSTGSS
//
